Company Plans to Develop New Prescription Products for Treatment of Nipple Neuropathies in Breast Cancer Patients
Jupiter Wellness, Inc. JUPW announced that it has signed an exclusive licensing agreement with Rejoy, Inc., a California Corporation, to develop prescription products for the treatment of nipple neuropathies and associated sexual problems in women that have been treated for breast cancer.
The exclusive license includes issued patents and technology, including formulations. In clinical studies, one topical formulation improved nipple sensitivity and alleviated associated sexual problems. Concomitantly, the formulation was also shown to increase female sexual lubrication and improve overall orgasmic response.
The product has been named JW-500 to be added to a line of other clinical stage products currently under development at the Company. Jupiter Wellness plans to file for a pre-IND meeting with the US FDA within the next 12 months and intends to seek Orphan Drug Designation. An expedited 505 (b)(2) regulatory pathway for development is anticipated as the current formulation contains an already approved drug.
“We are very pleased to have secured this license agreement with Rejoy, Inc., as it builds upon our acquisition of Applied Biology assets and clears the path for us to build on the prior work by Rejoy and Applied Biology,” said Brian John, CEO of Jupiter Wellness.
The 505 (b)(2) pathway provides a pathway for FDA approval without having to complete all the steps typically required for new pharmaceuticals and provides an alternate option for developing drugs from already known compounds to address new indications.
Image sourced from Unsplash
This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice.